Accendra Health Inc (NYSE: ACH) on Monday, soared 8.94% from the previous trading day, before settling in for the closing price of $2.46. Within the past 52 weeks, ACH’s price has moved between $1.84 and $15.54.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -35.63%. The company achieved an average annual earnings per share of -33.74%. With a float of $74.42 million, this company’s outstanding shares have now reached $77.30 million.
Accendra Health Inc (ACH) Insider and Institutional Ownership
Observing investor behavior towards Medical Distribution industry stocks is more important than anything else. The insider ownership of Accendra Health Inc is 3.78%, while institutional ownership is 101.46%. The most recent insider transaction that took place on Aug 12 ’25, was worth 3,708,000. In this transaction 10% Owner of this company bought 720,000 shares at a rate of $5.15, taking the stock ownership to the 12,282,955 shares. Before that another transaction happened on Aug 14 ’25, when Company’s 10% Owner bought 492,852 for $5.31, making the entire transaction worth $2,617,044. This insider now owns 13,100,807 shares in total.
Accendra Health Inc (ACH) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.55 earnings per share (EPS) for the period topping the consensus outlook (set at 0.52) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -33.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.42% during the next five years compared to -35.63% drop over the previous five years of trading.
Accendra Health Inc (NYSE: ACH) Trading Performance Indicators
Accendra Health Inc (ACH) is currently performing well based on its current performance indicators. A quick ratio of 0.84 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -17.40, a number that is poised to hit 0.22 in the next quarter and is forecasted to reach 0.96 in one year’s time.
